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ighly Sensitive Troponins
he Answer or Just More Questions?*
udd E. Hollander, MD
hiladelphia, Pennsylvania
n 2006, the Institute of Medicine released a report detail-
ng the crisis in emergency care (1). Our current approach to
he care of patients with potential acute coronary syndromes
ACS) has contributed to this crisis. Physicians admit the
ajority of the 6 million patients that present to the
mergency department (ED) with signs and symptoms of a
ossible ACS (2), yet a relatively small percentage actually
urn out to have a cardiac etiology for their chest pain. The
onsequences of this practice have resulted in expenses
xceeding $8 to $10 billion annually to rule out acute
yocardial infarction (AMI) and ACS (3,4). Nonetheless,
See page 1165
t should be noted that there are more negative conse-
uences than simply cost. As ED patient volumes have
rown disproportionately to inpatient bed availability,
oarding of admitted patients has become commonplace
1,2). Patients with chest pain syndromes are the most
ommon cohort of patients boarding in the ED awaiting
dmission (3). Emergency department crowding has re-
ently been proven to have an adverse impact on important
atient-oriented outcomes across a broad spectrum of dis-
ases (5–8). In particular, patients with ACS have an
ncreased risk of short-term adverse outcomes when they
resent to the ED during more crowded times (7). Thus, it
s more important than ever to be able to distinguish
atients with ACS from those with a noncardiac etiology
arly in the evaluation.
Decades of well-thought-out clinical studies have pro-
ided a wealth of information regarding risk of AMI and
dverse cardiovascular outcomes. Risk stratification tools,
uch as the Goldman rule, ACI-TIPI (Acute Cardiac
schemia-Time Insensitive Predictive Instrument), and
hrombolysis In Myocardial Infarction risk score distin-
uish high-risk from low-risk patients (9–11). Unfortu-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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anosphere.ately, they do not allow physicians to reliably identify
atients who are safe for discharge from the ED without
erial cardiac markers or provocative testing.
Historically speaking, the initial plasma sample of a
ardiac marker detected no better than 30% to 40% of
atients with non–ST-segment elevation myocardial infarc-
ion (NSTEMI) (9). They have not been able to detect
nstable angina. Efforts to enhance the utility of cardiac
arkers to rapidly identify higher-risk patients with ACS as
ell as to enable the expeditious discharge of patients
ithout disease have focused on several approaches: more
requent serial sampling (12), combinations of markers
ased on release kinetics (13,14), and combinations of
ardiac markers based on the pathophysiology of AMI
15,16).
Although troponin and creatine kinase (CK)-MB have
pproximately the same rate of increase, when used together
t the time of ED presentation diagnostic sensitivity in-
reases more than 25% (17). A combination of myoglobin
nd CK-MB has a sensitivity of 85% at the time of
resentation. It attains a 100% sensitivity, specificity, and
egative predictive value within 4 h of ED presentation
14). Combinations of myoglobin and troponin I can
chieve a diagnostic sensitivity of 97% with a 99% negative
redictive value, within 90 min of ED presentation (12).
lthough combination strategies enhance sensitivity, they
eem to do so at the cost of specificity. They also do not
bviate the need for provocative testing or identify patients
ith unstable angina, and therefore have not been shown to
elp reduce the admission rate for patients ultimately found
o be disease free.
Although population-based studies of markers of inflam-
ation and platelet activation have found a relationship
etween marker elevations and long-term prognosis, similar
esults have not been found in the acute setting. Markers of
latelet activation such as P-selectin are theoretically attrac-
ive because they can detect platelet activation before myo-
ardial injury; however, they do not identify patients with
MI any better than CK-MB (15). The utility of inflam-
atory markers in longitudinal cohort studies do not seem
o apply to patients in the ED, where most patients with
otential ACS have confounding medical conditions that
ncrease the likelihood of abnormal values. Similarly, when
dded to markers of cell death, B-type natriuretic peptide
BNP), which is secreted from the ventricles in response to
ressure or volume overload, increases sensitivity for detec-
ion of patients with adverse cardiovascular outcomes, but at
he cost of decreased specificity (16).
Sometimes the answer to our wishes lies right beneath the
urface. The data reported by Venge et al. (18), in this issue
f the Journal, suggest that we might not need new markers,
e may just need better assays. Venge et al. (18) used a
ighly sensitive assay and found normal values of troponin
n a cohort of healthy asymptomatic patients. Using an
pper limit of normal derived from these healthy patients
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Highly Sensitive Troponins September 22, 2009:1173–5nd comparing it to values from the GUSTO-IV (Global
tilization of Strategies To open Occluded arteries IV) trial
ohort, they found a sensitivity of 85% and a specificity of
0% for death or MI. Wilson et al. (19) examined 50
STEMI patients with an initially negative troponin by
onventional assay using a nano-troponin I assay (99th
ercentile of 0.002 ng/ml) and found that 100% had
etectable levels within 2 h. In a similar evaluation of
nstable angina patients with documented negative tropo-
in values out to 24 h, 90% had detectable values using the
ano-troponin I (19). Our group has examined 10 patients
ith NSTEMI who had undetectable troponin values on
he initial sample using an older-generation troponin assay
upper reference limit, 600 pg/ml). Samples from these
atients at presentation, 90 min, and 180 min were mea-
ured by a highly sensitive assay (upper reference limit 2.8
g/ml). All 10 were35 pg/ml on the highly sensitive assay
t presentation (20). Thus, it seems highly likely that these
ighly sensitive troponin assays will allow us to detect many
STEMI patients earlier than current-generation assays. It
ay even enable the objective identification of patients with
nstable angina.
Ideally, a marker with a high sensitivity and high negative
redictive value is useful to allow expeditious evaluation and
ischarge from the ED. Markers with high specificity and
ositive predictive values are ideal to tailor care for patients
t high risk of cardiovascular complications. Both are
eeded to provide optimal management to all patients who
resent to the ED with potential ACS. Although none of us
ossesses a magic crystal ball, it seems reasonable to pre-
uppose that as with every other incremental improvement,
e will trade specificity for sensitivity. As the analytical
bility to measure troponin continues to move lower, we will
e forced to readjust our approach to patient management.
ssume that for every 100 patients presenting to the ED
ith symptoms possibly consistent with ACS, 65 are
dmitted to the hospital (5 to the cardiac care unit, 10 to
ardiology, and 50 to internists or hospitalists). At the end
f the hospitalization, 15 are diagnosed with ACS, 50 with
oncardiac etiologies of their symptoms. Now imagine that
highly sensitive troponin assay can achieve 94% sensitivity
n the initial sample, but will have only 80% specificity.
his new assay could reduce the admission rate from 65
atients to 31, enabling the discharge of 69 patients (nearly
oubling the discharge rate from 35) while maintaining a
iss rate of about 1%. From the ED perspective, it would
elp reduce overcrowding, thereby benefiting the larger
ubset of ED patients who may be subjected to harm from
ong waits to be evaluated and treated. From the perspective
f the internist or hospitalist, it would result in fewer
dmissions of patients without disease. However, it is
ossible that all 31 troponin-positive patients (of whom
nly 14 actually had disease) would be admitted to the
ardiology service, greatly increasing the percentage of
ossible ACS patients without disease to more than 50%. It
ight soon become time for the cardiologist, emergency
1hysician, and primary care provider to re-evaluate current
iagnostic and disposition pathways to maximize patient
utcomes. Future research will need to determine not only
he diagnostic and prognostic characteristics of these assays,
ut also the best way to translate their use into clinical
ractice. We will need to define the approach to manage-
ent of this new class of troponin-positive patients. They
ay or may not benefit from the usual cadre of our
vidence-based treatments.
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